Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 7/2014

01-07-2014 | Retinal Disorders

Intravitreal injection of 99Tc-MDP inhibits the development of laser-induced choroidal neovascularization in rhesus monkeys

Authors: Kunbei Lai, Chenjin Jin, Shu Tu, Yunfan Xiong, Rui Huang, Jian Ge

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 7/2014

Login to get access

Abstract

Background

The aim of this study was to investigate the safety and efficacy of intravitreal injection of 99Tc-MDP, a decay product of 99mTc-MDP, on the development of laser-induced choroidal neovascularization (CNV) in rhesus monkeys.

Methods

Experimental CNV was induced by argon laser with a small high-energy laser spot. Monkeys were given 50 μL of 99Tc-MDP at a concentration of 0.005 μg/mL (n = 6) or 0.01 μg/mL (n = 6) by intravitreal injection once a week immediately after laser injury for a period of 56 days. Control animals were treated with the same volume of PBS (n = 6) in the same way. Eyes were monitored by ophthalmic examination, color fundus photography, fluorescence fundus angiography (FFA), optical coherence tomography (OCT) and histology. Incidences of grade 4 CNV lesions as well as the leakage areas of grade 4 CNVs on the late-phase of fluorescein angiograms were measured in a standardized, randomized and masked fashion fortnightly. The maximum widths and heights of grade 4 CNVs were also calculated by histology at the end of the experiment. Toxicity of 99Tc-MDP on the retina was evaluated by electroretinogram (ERG) and histologic analysis.

Results

99Tc-MDP reduced the incidences of grade 4 CNVs by 33.33 % and 39.40 % in the 0.005 μg/mL and 0.01 μg/mL groups, respectively, compared with the PBS group on day 28 (P < 0.05; n = 6). The leakage areas of grade 4 CNVs were smaller in the 0.005 μg/mL (0.7136 ± 0.0283 mm2, p <0.01; n = 6) and 0.01 μg/mL (0.4351 ± 0.0349 mm2, p < 0.01; n = 6) groups than those in the PBS control group (0.9373 ± 0.0455 mm2; n = 6) in a dose-dependent manner on day 28. OCT and histology also showed that the sizes of CNVs were smaller in the 99Tc-MDP treated groups than those in the PBS group. Although intravitreal injection of 99Tc-MDP led to mild inflammatory reaction in the anterior chamber, histology and ERG findings demonstrated that 99Tc-MDP did not cause any change in histological structure or function of the retina (p>0.05).

Conclusions

Intravitreal injection of 99Tc-MDP can inhibit the development of laser-induced CNV without toxic effect on retina, suggesting that 99Tc-MDP has therapeutic potential for CNV related diseases.
Literature
2.
go back to reference Bressler NM, Frost LA, Bressler SB, Murphy RP, Fine SL (1988) Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol 106:1537–1542PubMedCrossRef Bressler NM, Frost LA, Bressler SB, Murphy RP, Fine SL (1988) Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol 106:1537–1542PubMedCrossRef
4.
go back to reference Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122:598–614PubMedCrossRef Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122:598–614PubMedCrossRef
5.
go back to reference Oh H, Takagi H, Takagi C, Suzuma K, Otani A, Ishida K, Matsumura M, Ogura Y, Honda Y (1999) The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40:1891–1898PubMed Oh H, Takagi H, Takagi C, Suzuma K, Otani A, Ishida K, Matsumura M, Ogura Y, Honda Y (1999) The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40:1891–1898PubMed
6.
go back to reference Pollack A, Korte GE, Heriot WJ, Henkind P (1986) Ultrastructure of Bruch’s membrane after krypton laser photocoagulation. II. Repair of Bruch’s membrane and the role of macrophages. Arch Ophthalmol 104:1377–1382PubMedCrossRef Pollack A, Korte GE, Heriot WJ, Henkind P (1986) Ultrastructure of Bruch’s membrane after krypton laser photocoagulation. II. Repair of Bruch’s membrane and the role of macrophages. Arch Ophthalmol 104:1377–1382PubMedCrossRef
7.
go back to reference Kimura H, Spee C, Sakamoto T, Hinton DR, Ogura Y, Tabata Y, Ikada Y, Ryan SJ (1999) Cellular response in subretinal neovascularization induced by bFGF-impregnated microspheres. Invest Ophthalmol Vis Sci 40:524–528PubMed Kimura H, Spee C, Sakamoto T, Hinton DR, Ogura Y, Tabata Y, Ikada Y, Ryan SJ (1999) Cellular response in subretinal neovascularization induced by bFGF-impregnated microspheres. Invest Ophthalmol Vis Sci 40:524–528PubMed
8.
go back to reference Lopez PF, Grossniklaus HE, Lambert HM, Aaberg TM, Capone A Jr, Sternberg P Jr, L’Hernault N (1991) Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 112:647–656PubMed Lopez PF, Grossniklaus HE, Lambert HM, Aaberg TM, Capone A Jr, Sternberg P Jr, L’Hernault N (1991) Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 112:647–656PubMed
9.
go back to reference Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, Elner VM, Elner SG, Sternberg P Jr (2002) Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8:119–126PubMed Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, Elner VM, Elner SG, Sternberg P Jr (2002) Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8:119–126PubMed
10.
go back to reference Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J (2003) Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3578–3585PubMedCrossRef Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J (2003) Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3578–3585PubMedCrossRef
11.
go back to reference Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW (2003) Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3586–3592PubMedCrossRef Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW (2003) Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3586–3592PubMedCrossRef
12.
go back to reference Yeh DC, Bula DV, Miller JW, Gragoudas ES, Arroyo JG (2004) Expression of leukocyte adhesion molecules in human subfoveal choroidal neovascular membranes treated with and without photodynamic therapy. Invest Ophthalmol Vis Sci 45:2368–2373PubMedCrossRef Yeh DC, Bula DV, Miller JW, Gragoudas ES, Arroyo JG (2004) Expression of leukocyte adhesion molecules in human subfoveal choroidal neovascular membranes treated with and without photodynamic therapy. Invest Ophthalmol Vis Sci 45:2368–2373PubMedCrossRef
13.
go back to reference Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J (2003) Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 44:2743–2749PubMedCrossRef Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J (2003) Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 44:2743–2749PubMedCrossRef
14.
go back to reference Cousins SW, Espinosa-Heidmann DG, Csaky KG (2004) Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? Arch Ophthalmol 122:1013–1018PubMedCrossRef Cousins SW, Espinosa-Heidmann DG, Csaky KG (2004) Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? Arch Ophthalmol 122:1013–1018PubMedCrossRef
15.
go back to reference Shi X, Semkova I, Muther PS, Dell S, Kociok N, Joussen AM (2006) Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp Eye Res 83:1325–1334PubMedCrossRef Shi X, Semkova I, Muther PS, Dell S, Kociok N, Joussen AM (2006) Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp Eye Res 83:1325–1334PubMedCrossRef
16.
go back to reference Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N (2004) Association between C-reactive protein and age-related macular degeneration. JAMA 291:704–710PubMedCrossRef Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N (2004) Association between C-reactive protein and age-related macular degeneration. JAMA 291:704–710PubMedCrossRef
17.
go back to reference Boekhoorn SS, Vingerling JR, Witteman JC, Hofman A, de Jong PT (2007) C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol 125:1396–1401PubMedCrossRef Boekhoorn SS, Vingerling JR, Witteman JC, Hofman A, de Jong PT (2007) C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol 125:1396–1401PubMedCrossRef
18.
go back to reference Libby P, Ridker PM (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116(Suppl 6A):9S–16SPubMedCrossRef Libby P, Ridker PM (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116(Suppl 6A):9S–16SPubMedCrossRef
19.
go back to reference Jiang N, Liang J, Lu X, Liu S, Zhong F, Wu J (2000) Analysis of the response to treatment of rheumatoid arthritis with 99Tc-MDP. J Mod Clin Med Bioeng 6:180–182 Jiang N, Liang J, Lu X, Liu S, Zhong F, Wu J (2000) Analysis of the response to treatment of rheumatoid arthritis with 99Tc-MDP. J Mod Clin Med Bioeng 6:180–182
20.
go back to reference Mu R, Chen S, Li Z, Ren L (2004) Therapeutic effect of 99Tc-MDP and its role in proinflammatory cytokines in rheumatoid arthritis. Chin J Rheumatol 8:39–41 Mu R, Chen S, Li Z, Ren L (2004) Therapeutic effect of 99Tc-MDP and its role in proinflammatory cytokines in rheumatoid arthritis. Chin J Rheumatol 8:39–41
21.
go back to reference Wang L, Gu Q, Xu Y, Li S, Gui J, Yang J, Yao Q, Ji Y (2008) Effects of Yunke (technetium-99 conjugated with methylene diphosphonate; (99)Tc-MDP) and/or colloidal chromic phosphate phosphonium-32, alone and in combination, in rats with adjuvant arthritis. Clin Exp Pharmacol Physiol 35:23–28PubMedCrossRef Wang L, Gu Q, Xu Y, Li S, Gui J, Yang J, Yao Q, Ji Y (2008) Effects of Yunke (technetium-99 conjugated with methylene diphosphonate; (99)Tc-MDP) and/or colloidal chromic phosphate phosphonium-32, alone and in combination, in rats with adjuvant arthritis. Clin Exp Pharmacol Physiol 35:23–28PubMedCrossRef
22.
go back to reference Lai K, Xu L, Jin C, Wu K, Tian Z, Huang C, Zhong X, Ye H (2011) Technetium-99 conjugated with methylene diphosphonate (99Tc-MDP) inhibits experimental choroidal neovascularization in vivo and VEGF-induced cell migration and tube formation in vitro. Invest Ophthalmol Vis Sci 52:5702–5712PubMedCrossRef Lai K, Xu L, Jin C, Wu K, Tian Z, Huang C, Zhong X, Ye H (2011) Technetium-99 conjugated with methylene diphosphonate (99Tc-MDP) inhibits experimental choroidal neovascularization in vivo and VEGF-induced cell migration and tube formation in vitro. Invest Ophthalmol Vis Sci 52:5702–5712PubMedCrossRef
23.
go back to reference Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, Gragoudas ES (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427–438PubMedCrossRef Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, Gragoudas ES (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427–438PubMedCrossRef
24.
go back to reference Husain D, Miller JW, Michaud N, Connolly E, Flotte TJ, Gragoudas ES (1996) Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 114:978–985PubMedCrossRef Husain D, Miller JW, Michaud N, Connolly E, Flotte TJ, Gragoudas ES (1996) Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 114:978–985PubMedCrossRef
25.
go back to reference Ryan SJ (1982) Subretinal neovascularization. Natural history of an experimental model. Arch Ophthalmol 100:1804–1809PubMedCrossRef Ryan SJ (1982) Subretinal neovascularization. Natural history of an experimental model. Arch Ophthalmol 100:1804–1809PubMedCrossRef
26.
go back to reference Ohkuma H, Ryan SJ (1983) Experimental subretinal neovascularization in the monkey. Permeability of new vessels. Arch Ophthalmol 101:1102–1110PubMedCrossRef Ohkuma H, Ryan SJ (1983) Experimental subretinal neovascularization in the monkey. Permeability of new vessels. Arch Ophthalmol 101:1102–1110PubMedCrossRef
27.
go back to reference Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O’Neill CA, Miller JW (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120:338–346PubMedCrossRef Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O’Neill CA, Miller JW (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120:338–346PubMedCrossRef
28.
go back to reference Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, Connolly EJ, Michaud N, Gragoudas ES, O’Neill CA, Beyer JC, Miller JW (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123:509–516PubMedCrossRef Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, Connolly EJ, Michaud N, Gragoudas ES, O’Neill CA, Beyer JC, Miller JW (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123:509–516PubMedCrossRef
29.
go back to reference Messias A, Gekeler F, Wegener A, Dietz K, Kohler K, Zrenner E (2008) Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography. Doc Ophthalmol 116:177–191PubMedCrossRef Messias A, Gekeler F, Wegener A, Dietz K, Kohler K, Zrenner E (2008) Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography. Doc Ophthalmol 116:177–191PubMedCrossRef
30.
go back to reference Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29:95–112PubMedCentralPubMedCrossRef Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29:95–112PubMedCentralPubMedCrossRef
32.
go back to reference Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002) A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134:411–431PubMedCrossRef Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002) A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134:411–431PubMedCrossRef
33.
go back to reference Nagai N, Oike Y, Izumi-Nagai K, Urano T, Kubota Y, Noda K, Ozawa Y, Inoue M, Tsubota K, Suda T, Ishida S (2006) Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 26:2252–2259PubMedCrossRef Nagai N, Oike Y, Izumi-Nagai K, Urano T, Kubota Y, Noda K, Ozawa Y, Inoue M, Tsubota K, Suda T, Ishida S (2006) Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 26:2252–2259PubMedCrossRef
34.
go back to reference Penfold PL, Madigan MC, Gillies MC, Provis JM (2001) Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 20:385–414PubMedCrossRef Penfold PL, Madigan MC, Gillies MC, Provis JM (2001) Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 20:385–414PubMedCrossRef
35.
go back to reference McGeer PL, Sibley J (2005) Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiol Aging 26:1199–1203PubMedCrossRef McGeer PL, Sibley J (2005) Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiol Aging 26:1199–1203PubMedCrossRef
36.
go back to reference Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRef Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRef
37.
go back to reference Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908PubMedCrossRef Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908PubMedCrossRef
38.
go back to reference Lux A, Llacer H, Heussen FM, Joussen AM (2007) Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 91:1318–1322PubMedCentralPubMedCrossRef Lux A, Llacer H, Heussen FM, Joussen AM (2007) Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 91:1318–1322PubMedCentralPubMedCrossRef
39.
go back to reference Spaide RF (2009) Rationale for combination therapy in age-related macular degeneration. Retina 29:S5–S7PubMedCrossRef Spaide RF (2009) Rationale for combination therapy in age-related macular degeneration. Retina 29:S5–S7PubMedCrossRef
40.
go back to reference de Oliveira Dias JR, Rodrigues EB, Maia M, Magalhaes O Jr, Penha FM, Farah ME (2011) Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 95:1631–1637PubMedCrossRef de Oliveira Dias JR, Rodrigues EB, Maia M, Magalhaes O Jr, Penha FM, Farah ME (2011) Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 95:1631–1637PubMedCrossRef
Metadata
Title
Intravitreal injection of 99Tc-MDP inhibits the development of laser-induced choroidal neovascularization in rhesus monkeys
Authors
Kunbei Lai
Chenjin Jin
Shu Tu
Yunfan Xiong
Rui Huang
Jian Ge
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2014
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-013-2559-1

Other articles of this Issue 7/2014

Graefe's Archive for Clinical and Experimental Ophthalmology 7/2014 Go to the issue